151 related articles for article (PubMed ID: 20029238)
1. Growth hormone and the heart in Noonan syndrome.
Noordam C
Horm Res; 2009 Dec; 72 Suppl 2():49-51. PubMed ID: 20029238
[TBL] [Abstract][Full Text] [Related]
2. Noonan syndrome: growth to growth hormone - the experience of observational studies.
Ranke MB
Horm Res; 2009 Dec; 72 Suppl 2():36-40. PubMed ID: 20029235
[TBL] [Abstract][Full Text] [Related]
3. Abnormal growth in noonan syndrome: the challenge of optimal therapy.
Savage MO; Padidela R; Kirk JM; Malaquias AC; Jorge AA
Pediatr Endocrinol Rev; 2009 Jun; 6 Suppl 4():523-8. PubMed ID: 19550387
[TBL] [Abstract][Full Text] [Related]
4. Noonan syndrome: introduction and basic clinical features.
Rohrer T
Horm Res; 2009 Dec; 72 Suppl 2():3-7. PubMed ID: 20029230
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone therapy in Noonan syndrome: growth response and characteristics.
Westphal O
Horm Res; 2009 Dec; 72 Suppl 2():41-5. PubMed ID: 20029236
[TBL] [Abstract][Full Text] [Related]
6. Response to growth hormone in short children with Noonan syndrome: correlation to genotype.
Binder G
Horm Res; 2009 Dec; 72 Suppl 2():52-6. PubMed ID: 20029239
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation.
Kobayashi T; Aoki Y; Niihori T; Cavé H; Verloes A; Okamoto N; Kawame H; Fujiwara I; Takada F; Ohata T; Sakazume S; Ando T; Nakagawa N; Lapunzina P; Meneses AG; Gillessen-Kaesbach G; Wieczorek D; Kurosawa K; Mizuno S; Ohashi H; David A; Philip N; Guliyeva A; Narumi Y; Kure S; Tsuchiya S; Matsubara Y
Hum Mutat; 2010 Mar; 31(3):284-94. PubMed ID: 20052757
[TBL] [Abstract][Full Text] [Related]
8. GH therapy in Noonan syndrome: Review of final height data.
Dahlgren J
Horm Res; 2009 Dec; 72 Suppl 2():46-8. PubMed ID: 20029237
[TBL] [Abstract][Full Text] [Related]
9. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11.
Noordam C; Peer PG; Francois I; De Schepper J; van den Burgt I; Otten BJ
Eur J Endocrinol; 2008 Sep; 159(3):203-8. PubMed ID: 18562489
[TBL] [Abstract][Full Text] [Related]
10. The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene.
Sznajer Y; Keren B; Baumann C; Pereira S; Alberti C; Elion J; Cavé H; Verloes A
Pediatrics; 2007 Jun; 119(6):e1325-31. PubMed ID: 17515436
[TBL] [Abstract][Full Text] [Related]
11. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
Ferreira LV; Souza SA; Arnhold IJ; Mendonca BB; Jorge AA
J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
[TBL] [Abstract][Full Text] [Related]
12. [New findings in Noonan syndrome and Leopard syndrome: activating mutations in RAF-1 and SOS-1].
Dereure O
Ann Dermatol Venereol; 2008; 135(8-9):624-5. PubMed ID: 18789305
[No Abstract] [Full Text] [Related]
13. Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients.
Ferreira LV; Souza SC; Montenegro LR; Malaquias AC; Arnhold IJ; Mendonca BB; Jorge AA
Clin Endocrinol (Oxf); 2008 Sep; 69(3):426-31. PubMed ID: 18331608
[TBL] [Abstract][Full Text] [Related]
14. Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors.
Mutesa L; Pierquin G; Janin N; Segers K; Thomée C; Provenzi M; Bours V
Cancer Genet Cytogenet; 2008 Apr; 182(1):40-2. PubMed ID: 18328949
[TBL] [Abstract][Full Text] [Related]
15. Germline gain-of-function mutations in RAF1 cause Noonan syndrome.
Razzaque MA; Nishizawa T; Komoike Y; Yagi H; Furutani M; Amo R; Kamisago M; Momma K; Katayama H; Nakagawa M; Fujiwara Y; Matsushima M; Mizuno K; Tokuyama M; Hirota H; Muneuchi J; Higashinakagawa T; Matsuoka R
Nat Genet; 2007 Aug; 39(8):1013-7. PubMed ID: 17603482
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of DNET and other brain tumors in Noonan syndrome warrants caution with growth hormone therapy.
McWilliams GD; SantaCruz K; Hart B; Clericuzio C
Am J Med Genet A; 2016 Jan; 170A(1):195-201. PubMed ID: 26377682
[TBL] [Abstract][Full Text] [Related]
17. Pilocytic astrocytoma in a child with Noonan syndrome.
Schuettpelz LG; McDonald S; Whitesell K; Desruisseau DM; Grange DK; Gurnett CA; Wilson DB
Pediatr Blood Cancer; 2009 Dec; 53(6):1147-9. PubMed ID: 19621452
[TBL] [Abstract][Full Text] [Related]
18. Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation.
Choi JH; Lee BH; Jung CW; Kim YM; Jin HY; Kim JM; Kim GH; Hwang JS; Yang SW; Lee J; Yoo HW
Horm Res Paediatr; 2012; 77(6):388-93. PubMed ID: 22777296
[TBL] [Abstract][Full Text] [Related]
19. [The Noonan syndrome from a pediatric perspective].
Noordam C; Thoonen G; van der Burgt CJ
Ned Tijdschr Geneeskd; 2003 Apr; 147(14):644-8. PubMed ID: 12712646
[TBL] [Abstract][Full Text] [Related]
20. Atypical granular cell tumor occurring in an individual with Noonan syndrome treated with growth hormone.
Moos D; Droitcourt C; Rancherevince D; Marec Berard P; Skowron F
Pediatr Dermatol; 2012; 29(5):665-6. PubMed ID: 22329457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
